Anew Medical, Inc. (WENA)
NASDAQ: WENA · IEX Real-Time Price · USD
1.480
-0.060 (-3.90%)
At close: Jul 19, 2024, 4:00 PM
1.510
+0.030 (2.03%)
Pre-market: Jul 22, 2024, 8:11 AM EDT
Company Description
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics.
Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.
The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
Anew Medical, Inc. is based in Omaha, Nebraska.
Anew Medical, Inc.
| Country | NY |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Peter J. Moriarty |
Contact Details
Address: 1115 Broadway, 12th Floor New York, New York 10010 United States | |
| Phone | 646-916-5315 |
Stock Details
| Ticker Symbol | WENA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jiande Chen | Chairman, President and Chief Executive Officer |
| Cong Wang | Chief Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 25-NSE | Filing |
| Jun 20, 2024 | 425 | Filing |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 425 | Filing |
| Jun 14, 2024 | 8-K/A | [Amend] Current report |
| Jun 14, 2024 | 425 | Filing |
| Jun 14, 2024 | 8-K | Current Report |
| May 23, 2024 | 10-Q | Quarterly Report |